Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study

In our single-center study, 357 myeloma and lymphoma patients between 2009 and 2019 were mobilized with granulocyte colony-stimulating factor (G-CSF 7.5 µg/kg bid for four days) plus a fixed dose of 24 mg Plerixafor when indicated (Plerixafor Group, <i>n</i> = 187) or G-CSF alone (G-CSF...

Full description

Bibliographic Details
Main Authors: Normann Steiner, Georg Göbel, Leonie Mauser, Lena Mühlnikel, Marie Fischinger, Tina Künz, Wolfgang Willenbacher, Gabriele Hetzenauer, Jakob Rudzki, Walter Nussbaumer, Wolfgang Mayer, Eberhard Gunsilius, Brigitte Kircher, Dominik Wolf, David Nachbaur
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
lymphoma
multiple myeloma
autologous stem cell transplantation
granulocyte colony-stimulating factor
Plerixafor
poor mobilizer
Online Access:https://www.mdpi.com/2072-6694/15/3/608

Internet

https://www.mdpi.com/2072-6694/15/3/608

Similar Items